Condition

B Acute Lymphoblastic Leukemia clinical trials and research

• 11Clinical trials
• 7Countries

Newest B Acute Lymphoblastic Leukemia clinical trials

All recruiting trials (11)

• In vivo CAR-T therapy for relapsed or refractory B‑cell leukemias, lymphomas, and multiple myeloma

  This trial will try a single in‑body (intravenous) CAR‑T infusion to treat adults with relapsed or refractory B‑cell acute lymphoblastic leukemia, B‑cell non‑Hodgkin lymphoma, or multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07239323

• JY231 injection to treat relapsed or refractory B‑cell lymphoma and leukemia

  This study will try an in‑body CAR‑T therapy called JY231 for people aged 12–75 with relapsed or refractory CD19‑positive B‑cell lymphoma or B‑ALL.

  Recruiting Affiliated Hospital of Guangdong Medical University · Guangzhou, Guangdong · NCT06940960

• JY231 injection for treating relapsed or refractory B cell lymphoma and leukemia

  This study is testing a new injection called JY231 to see if it can help people with relapsed or hard-to-treat B cell lymphoma and leukemia feel better.

  Recruiting Shenzhen Genocury Biotech Co., Ltd. · Zhengzhou, Henan · NCT06890065

• Lower versus higher hemoglobin thresholds for red blood cell transfusions in adults with high-grade myeloid cancers or B-cell ALL/lymphoma

  This will see if giving transfusions only when hemoglobin drops to 7 g/dL instead of 9 g/dL affects quality of life and physical functioning for adults receiving intensive chemotherapy or allogeneic stem cell transplant for high-grade myeloid cancers or B-cell ALL/lymphoma.

  Recruiting University of Washington · Seattle, Washington · NCT06710418

• Combining venetoclax and blinatumomab with standard chemotherapy for infants with acute leukemia

  This study is testing whether adding two new treatments, venetoclax and blinatumomab, to standard chemotherapy can help infants with acute leukemia do better and stay cancer-free longer.

  Recruiting at 117 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 116 other locations · NCT06317662

• Combining blinatumomab with dasatinib or imatinib plus chemotherapy for young people with Ph+ or ABL-class Ph-like B‑ALL

  This pilot will see if adding three cycles of blinatumomab and a continuous tyrosine kinase inhibitor (dasatinib or imatinib) to a modified chemotherapy plan helps children, adolescents, and young adults with Ph+ or ABL-class Ph-like B‑ALL stay in remission longer.

  Recruiting at 159 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 160 other locations · NCT06124157

• Combining an anti-PD1 antibody with CAR T-cell therapy for young patients with relapsed leukemia

  This study is testing if adding a new drug to CAR T-cell therapy can help young patients with relapsed leukemia get better results from their treatment.

  Recruiting at 13 sites Phase 1/2 Assistance Publique - Hôpitaux de Paris · Bordeaux and 12 other locations · NCT05310591

• Local production of CAR T-cells for treating B-Cell cancers

  This study is testing whether making CAR T-cells locally can help patients with B-Cell lymphoma and leukemia have a safe and effective treatment.

  Recruiting Phase 2 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT05281809

• Using inotuzumab ozogamicin with chemotherapy for high-risk B-cell leukemia

  This study is testing if adding a targeted therapy called inotuzumab ozogamicin to standard chemotherapy can help young patients with high-risk B-cell leukemia live longer without their cancer coming back.

  Recruiting at 212 sites Phase 3 Children's Oncology Group · Birmingham, Alabama and 230 other locations · NCT03959085

• Inotuzumab ozogamicin with frontline chemotherapy for young adults with B‑cell acute lymphoblastic leukemia

  This trial tests whether adding the antibody-drug inotuzumab ozogamicin to a pediatric-style frontline chemotherapy plan helps young adults with newly diagnosed CD22-positive B acute lymphoblastic leukemia live longer without relapse.

  Recruiting at 157 sites Phase 3 Alliance for Clinical Trials in Oncology · Birmingham, Alabama and 459 other locations · NCT03150693

• Using blinatumomab, inotuzumab ozogamicin, and chemotherapy to treat B acute lymphoblastic leukemia

  This study is testing a new combination of two immunotherapy drugs and chemotherapy to see if it helps people with newly diagnosed B acute lymphoblastic leukemia live longer and stay cancer-free.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT02877303

Related topics

Quick answers

How many B Acute Lymphoblastic Leukemia clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 7 countries. The most sites are in United States (7 trials), Canada (3 trials), Puerto Rico (3 trials), China (3 trials), Australia (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 3: 2, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →